Advanced Techniques and Awaited Clinical Applications for Human Pluripotent Stem Cell Differentiation into Hepatocytes

Eléanor Luce, Antonietta Messina, Jean‐Charles Duclos‐Vallée, Anne Dubart‐Kupperschmitt – 7 January 2021 – Liver transplantation is currently the only curative treatment for several liver diseases such as acute liver failure, end‐stage liver disorders, primary liver cancers, and certain genetic conditions. Unfortunately, despite improvements to transplantation techniques, including live donor transplantation, the number of organs available remains insufficient to meet patient needs.

National Early Career Transplant Hepatologist Survey: Compensation, Burnout, and Job Satisfaction

Michael Kriss, Helen S. Te, Elizabeth C. Verna, Lisa B. VanWagner, Frank I. Scott, Jennifer C. Lai – 4 January 2021 – Despite the growth of transplant hepatology as a subspecialty over the past decade, data on professional roles and compensation models remain lacking. Furthermore, the prevalence of physician burnout and job satisfaction are unknown in this profession. We aimed to conduct a comprehensive assessment of early career transplant hepatologists to fill these voids in knowledge and to inform current and future transplant hepatologists.

Prognostic Value of the CLIF‐C AD Score in Patients With Implantation of Transjugular Intrahepatic Portosystemic Shunt

Lukas Sturm, Michael Praktiknjo, Dominik Bettinger, Jan P. Huber, Lara Volkwein, Arthur Schmidt, Rafael Kaeser, Johannes Chang, Christian Jansen, Carsten Meyer, Daniel Thomas, Robert Thimme, Jonel Trebicka, Michael Schultheiß – 4 January 2021 – Prognostic assessment of patients with liver cirrhosis allocated for implantation of a transjugular intrahepatic portosystemic shunt (TIPS) is a challenging task in clinical practice. The aim of our study was to assess the prognostic value of the CLIF‐C AD (Acute Decompensation) score in patients with TIPS implantation.

Serum Bile Acid, Vitamin E, and Serotonin Metabolites Are Associated With Future Liver‐Related Events in Nonalcoholic Fatty Liver Disease

Kara Wegermann, Catherine Howe, Ricardo Henao, Ying Wang, Cynthia D. Guy, Manal F. Abdelmalek, Anna Mae Diehl, Cynthia A. Moylan – 4 January 2021 – Identifying patients at higher risk for poor outcomes from nonalcoholic fatty liver disease (NAFLD) remains challenging. Metabolomics, the comprehensive measurement of small molecules in biological samples, has the potential to reveal novel noninvasive biomarkers. The aim of this study was to determine if serum metabolite profiles in patients with NAFLD associate with future liver‐related events.

Subscribe to